We are live on ! Find out more
ADIL icon

Adial Pharmaceuticals
ADIL

16 hedge funds and large institutions have $70.8K invested in Adial Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

23% more funds holding

Funds holding: 13 → 16 (+3)

8% less capital inflows, than outflows

Capital inflows: $37.4K | Capital outflows: $40.6K

2.57% less ownership

Funds ownership: 3.65% → 1.08% (-2.6%)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$15K
2
HRT Financial
HRT Financial
New York
+$11.5K
3
Two Sigma Investments
Two Sigma Investments
New York
+$6.52K
4
Citigroup
Citigroup
New York
+$2.4K
5
Stone House Investment Management
Stone House Investment Management
Pennsylvania
+$1.63K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$21.4K
2
Virtu Financial
Virtu Financial
New York
-$17K
3
1620 Investment Advisors
1620 Investment Advisors
Massachusetts
-$2.28K

ADIL Hedge Fund Activity: Q2 2025 in Review

16 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2025, worth a combined $70.8K — down 54% from $153K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ADIL positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $15K. The largest seller was UBS Group, cutting an estimated $21.4K.

  • 16 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2025, up from 13 in Q1 2025.
  • Funds reported $70.8K of Adial Pharmaceuticals stock for Q2 2025, down 54% quarter-over-quarter.
  • 5 funds opened new Adial Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +3 holders.
  • The largest Adial Pharmaceuticals buyer in Q2 2025 was Jane Street, an estimated $15K added.
  • The largest Adial Pharmaceuticals seller in Q2 2025 was UBS Group, an estimated $21.4K sold.

Based on aggregated 13F filings for Q2 2025.